Resapp Health (RAP.AX) Stock Price
Resapp Health Price
Revenue has compounded at 16.1% per year over the past 17 years to 2.51 M AUD. Resapp Health's net margin stands at -282.1%, up from -7,509.7% several years earlier. Analysts set a median price target of 0.23 AUD, implying 966.4% above the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 366% above its 52-week low.
Resapp Health stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Resapp Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Resapp Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Resapp Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Resapp Health Price |
|---|---|
| 9/2/2026 | 0.02 AUD |
| 9/1/2026 | 0.02 AUD |
| 8/31/2026 | 0.02 AUD |
| 8/28/2026 | 0.03 AUD |
| 8/27/2026 | 0.03 AUD |
| 8/26/2026 | 0.03 AUD |
| 8/25/2026 | 0.03 AUD |
| 8/24/2026 | 0.03 AUD |
| 8/21/2026 | 0.03 AUD |
| 8/20/2026 | 0.03 AUD |
| 8/19/2026 | 0.03 AUD |
| 8/18/2026 | 0.03 AUD |
| 8/17/2026 | 0.03 AUD |
| 8/14/2026 | 0.03 AUD |
| 8/13/2026 | 0.03 AUD |
| 8/12/2026 | 0.02 AUD |
| 8/11/2026 | 0.03 AUD |
| 8/10/2026 | 0.03 AUD |
| 8/7/2026 | 0.03 AUD |
| 8/6/2026 | 0.03 AUD |
| 8/5/2026 | 0.03 AUD |
| 8/4/2026 | 0.03 AUD |
| 8/3/2026 | 0.03 AUD |
| 7/31/2026 | 0.03 AUD |
| 7/30/2026 | 0.03 AUD |
| 7/29/2026 | 0.03 AUD |
| 7/28/2026 | 0.03 AUD |
| 7/27/2026 | 0.03 AUD |
| 7/24/2026 | 0.02 AUD |
| 7/23/2026 | 0.03 AUD |
Resapp Health Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Resapp Health Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | 2.00 | 16.00 | 37.00 | 85.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 700.00 | 131.25 | 129.73 |
| – | – | – | – | – | – | -3.00 | -10.00 | -6.00 | -5.00 | -8.00 | -6.00 | -6.00 | – | – | – |
| – | – | – | – | – | – | – | – | – | – | – | – | -300.00 | – | – | – |
| – | – | – | – | – | – | -3.00 | -10.00 | -6.00 | -5.00 | -8.00 | -6.00 | -7.00 | – | – | – |
| – | – | – | – | – | – | – | 233.33 | -40.00 | -16.67 | 60.00 | -25.00 | 16.67 | – | – | – |
| 196.67 | 235.60 | 430.12 | 430.12 | 458.99 | 205.33 | 491.71 | 655.48 | 659.04 | 685.19 | 707.79 | 778.30 | 859.22 | 859.22 | 859.22 | 859.22 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Resapp Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Resapp Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Resapp Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Resapp Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Resapp Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Resapp Health stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Resapp Health Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Resapp Health business model & stock analysis
Resapp Health SWOT Analysis
Strengths
Resapp Health Ltd possesses several strengths that contribute to its success in the healthcare industry. Firstly, the company's proprietary technology offers a non-invasive and convenient solution for diagnosing respiratory conditions. This provides a competitive advantage over traditional diagnostic methods.
Furthermore, Resapp Health Ltd has a strong intellectual property portfolio, protecting their innovative technology and ensuring differentiation from competitors. This allows them to capitalize on their unique offering and maintain a strong market position.
Weaknesses
Despite its strengths, Resapp Health Ltd also faces certain weaknesses that need to be addressed for sustainable growth. One such weakness is the company's heavy reliance on partnerships and collaborations for commercialization and market penetration. This dependence exposes the company to potential risks, such as partnership failures or delays in product development.
Additionally, Resapp Health Ltd has limited financial resources compared to larger competitors in the industry. This could constrain their ability to invest in research and development, marketing efforts, and expanding their operations, potentially limiting their growth potential.
Opportunities
Resapp Health Ltd operates in a rapidly growing digital health market, which presents various opportunities for future success. The increasing adoption of telehealth services and remote patient monitoring creates a favorable market environment for the company's respiratory diagnostic solutions. By positioning themselves as a leader in this space, Resapp Health Ltd can capitalize on the growing demand for convenient and accurate healthcare solutions.
Furthermore, expanding their product offerings to cover other respiratory conditions and diseases opens up new avenues for revenue growth for Resapp Health Ltd. This diversification can help mitigate market risks and increase their market share.
Threats
Resapp Health Ltd faces several potential threats within the healthcare industry. One significant threat is the high level of competition from both established players and emerging start-ups with similar respiratory diagnostic solutions. These competitors may have greater financial resources, larger customer bases, or stronger brand recognition, posing a challenge to Resapp Health Ltd's market position.
Another threat is the ever-changing regulatory landscape in the healthcare industry. Compliance with evolving regulations and obtaining necessary approvals can be resource-intensive and time-consuming for Resapp Health Ltd. Failure to comply with regulatory requirements could result in delays or restrictions in product commercialization.
Resapp Health Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Resapp Health historical P/E ratio, EBIT multiple, and P/S ratio
Resapp Health annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Resapp Health shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Resapp Health stock splits
Current Resapp Health forecasts and price targets in September 2026
Analyst Price Targets 2026Resapp Health shareholder structure
| % | Name |
|---|---|
0.00587% | |
0.00000% |
Resapp Health Executives and Management Board
8 members · avg. age 58 · 13 % women
Management
Mr. Mike Connell
Vice President - Commercial
Ms. Nicki Farley
Company Secretary · since 2012
Board of Directors
David Mandel
Director · since 2009
Dr. Roger Aston
Non-Executive Chairman of the Board
Mr. Brian Leedman
Executive Director · since 2016
Mr. Simon Lill (58)
Director
Chris Ntoumenopoulos
Non-Executive Director
Mr. Michael Stein
Non-Executive Director
Resapp Health Supply Chain
Resapp Health Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.62 | -0.07 | -0.65 | ||
| 2 | 0.82 | 0.56 | -0.53 | ||
| 3 | -0.14 | 0.51 | -0.49 | ||
| 4 | 0.45 | 0.55 | -0.33 | ||
| 5 | 0.88 | 0.82 | 0.25 |
Frequently asked questions about Resapp Health
Resapp Health Ltd is a medical technology company that specializes in the development of innovative respiratory diagnostic and management solutions. Their business model revolves around designing and commercializing smartphone-based applications, algorithms, and software solutions for the diagnosis and management of respiratory conditions. By utilizing the power of artificial intelligence and machine learning, Resapp Health Ltd aims to provide accurate, accessible, and cost-effective respiratory healthcare to patients worldwide. With a focus on improving respiratory disease outcomes, their technologies have the potential to revolutionize the way respiratory conditions are diagnosed and managed, ultimately leading to better patient outcomes and reduced healthcare costs.
Resapp Health Ltd is primarily active in the healthcare industry.
The main competitors of Resapp Health Ltd in the market include companies such as ResMed Inc., Fisher & Paykel Healthcare Corporation Limited, and Masimo Corporation.
Resapp Health Ltd, an innovative healthcare company, has a notable history and background. Founded in 2014, Resapp is dedicated to developing digital healthcare solutions centered around respiratory diseases. The company focuses on creating intelligent software that can diagnose and manage respiratory conditions using cough sounds and patient data. Resapp Health Ltd operates in the global market and has expanded its reach by collaborating with renowned medical institutions and research centers. With its cutting-edge technology and a team of experienced professionals, Resapp Health Ltd strives to improve the healthcare landscape and provide effective solutions for respiratory health.
Resapp Health Ltd has achieved a number of significant milestones. They successfully developed and launched ResAppDx, a smartphone-based diagnostic test for respiratory diseases. The company also received regulatory clearance in both the United States and European Union for their products. Resapp Health Ltd has entered into partnerships with leading healthcare institutions and companies to advance their technology and expand their market reach. They have conducted several successful clinical studies validating the accuracy and effectiveness of their diagnostic platform. Resapp Health Ltd's continuous innovation and commitment to improving respiratory healthcare positions them as a leader in the field.
Resapp Health Ltd is primarily present in Australia and the United States.
Resapp Health Ltd is a leading digital health company that focuses on developing innovative solutions to improve respiratory diagnostics and management. The company's values revolve around delivering accurate, accessible, and cost-effective healthcare solutions. Resapp Health is committed to leveraging cutting-edge technology and research to positively impact patient outcomes and healthcare efficiency. With a customer-centric approach, the company prioritizes collaboration, transparency, and integrity in all its endeavors. By constantly pushing the boundaries of respiratory healthcare, Resapp Health aims to revolutionize the industry and make a meaningful difference in the lives of individuals worldwide.
Analysts currently set an average price target of 0.23 AUD for the Resapp Health stock (median: 0.23 AUD), implying +737.9 % versus the latest price. The consensus is based on 6 analyst ratings.
5 analysts currently rate the Resapp Health stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Resapp Health share trades at 0.01 EUR (0.02 AUD).
ResApp Health Ltd is an Australian company that develops innovative digital health solutions based on artificial intelligence. The company's business model is to optimize healthcare in various areas by offering its proprietary technologies and products. ResApp Health's main areas of focus are the diagnosis and treatment of respiratory diseases, particularly in children. The company has developed a patented technology that analyzes cough sounds to support the diagnosis of conditions such as asthma, bronchitis, or pneumonia. This technology is available in the form of a mobile app that allows parents and caregivers to record cough sounds and receive a diagnosis within minutes. ResApp Health has also developed products and technologies to support healthcare professionals in the diagnosis of respiratory diseases. The company has developed a portable device called "Smarthaler" that monitors patients' airways and captures measurements such as respiratory rate and volume. These data are transmitted in real-time to an app that helps doctors and nurses detect conditions early and respond to changes more quickly. Another division of ResApp Health is telemedicine. The company has developed a platform that allows patients and doctors to communicate from anywhere. This platform offers various telemedicine services such as video consultations, electronic prescriptions, or digital medical records. This allows patients, especially those in rural areas or with limited mobility, to benefit from better healthcare. ResApp Health works closely with medical institutions and research facilities to improve and develop its technologies and products. The company has partnerships with renowned research institutions such as the University of Queensland or the Cleveland Clinic to conduct clinical studies and validate its technologies. The business model of ResApp Health is based on a mixture of products and services that improve healthcare in an innovative and intuitive way. The patented technology for the diagnosis of respiratory diseases enables rapid and accurate diagnosis, while the portable device and telemedicine platform make healthcare more efficient and accessible. ResApp Health has a wide range of application areas such as pediatrics, geriatrics, or general medicine, making it a promising company in the field of digital health.
The revenue cannot currently be calculated for Resapp Health.
The profit cannot currently be calculated for Resapp Health.
The P/E ratio cannot be calculated for Resapp Health at the moment.
The P/S cannot be calculated for Resapp Health currently.
The Eulerpool Quality Score for Resapp Health is 4/10.
The ISIN of Resapp Health is AU000000RAP5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Resapp Health is RAP.AX. The ticker symbol is used to trade Resapp Health shares on the stock exchange.
Resapp Health paid dividends every year for the past 0 years.
Resapp Health is assigned to the 'Health' sector.
The dividends of Resapp Health are distributed in AUD.
Resapp Health stock
Resapp Health Peer Group
Resapp Health FIGI
All fundamentals and in-depth analysis of Resapp Health
Our stock analysis for Resapp Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resapp Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.